Search Articles
FRANKFURT, GERMANY – Bayer AG announced today that it is stopping worldwide sales of Trasylol, used to reduce bleeding, because a Canadian clinical study found use of the drug could increase risk of death. Trasylol is an aprotinin, which blocks enzymes that dissolve blood clots. In October, the U.S. FDA allowed Trasylol to remain on the market despite studies that showed increased risk of death and other side effects.
Categories /
Uncategorized
Subscribe to our free newsletters
Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.